None of the new generics have yet been approved as Health Canada continues to work through the submissions with the companies
"These GLP-1 agonists can be a two-in-one solution for diabetes and weight loss," Robert Fontana, MD, a Michigan Medicine hepatologist said in an online interview included in the Cure report, "maybe a three-in-one solution if they prove to be safe and effective for metabolic associated steatohepatitis as well." Troubling Pattern in Patient Adherence to GLP-1 Drug Therapy Despite their effectiveness, adhering to the injectable drugs have proven challenging
Between 50% and 57% of those on the highest dose achieved 20% or greater weight loss
has received consulting honoraria from Anii Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Oramed, and stock options from Altpep
Seek support from communities of people who have experienced the same thing